EP2389934A1 — Controlled-Release Tablet Formulations of Pregabalin
Assigned to Sanovel Ilac Sanayi ve Ticaret AS · Expires 2011-11-30 · 14y expired
What this patent protects
The present invention relates to a controlled-release tablet formulation which gels in the stomach, comprising pregabalin or a pharmaceutically acceptable salt thereof, and a complex of sodium alginate and calcium chloride, or calcium alginate, or a properly-proportioned mixture …
USPTO Abstract
The present invention relates to a controlled-release tablet formulation which gels in the stomach, comprising pregabalin or a pharmaceutically acceptable salt thereof, and a complex of sodium alginate and calcium chloride, or calcium alginate, or a properly-proportioned mixture thereof as a controlled-release agent.
Drugs covered by this patent
- Lyrica (Pregabalin) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.